Targeted Oncology4d
Dandapani Explores Radium-223 Combination in Metastatic Prostate Cancer
Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...
Targeted Oncology7d
Phase 3 PEACE-3 Study of Enzalutamide + Ra-223: Efficacy Data
Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide ...
Daily8d
Treatment Gaps: GLP-1 RA Discontinuation Higher in Patients Without Type 2 Diabetes, Study Finds
Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...
Oncology Nurse Advisor3d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...